^
    1d
    Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies (clinicaltrials.gov)
    P2, N=20, Completed, University of Washington | Active, not recruiting --> Completed | Trial completion date: Aug 2029 --> Jan 2026
    Trial completion • Trial completion date
    |
    Opdivo (nivolumab)
    1d
    CD70-targeted immunoPET Imaging of Malignant Cancers (clinicaltrials.gov)
    P2, N=300, Recruiting, RenJi Hospital | Phase classification: P=N/A --> P2
    Phase classification
    |
    CD70 (CD70 Molecule)
    2d
    Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies (clinicaltrials.gov)
    P2, N=20, Recruiting, University of Washington | N=40 --> 20 | Trial completion date: Jul 2027 --> Jul 2028 | Trial primary completion date: Dec 2026 --> Dec 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Zynlonta (loncastuximab tesirine-lpyl) • AMG 211
    3d
    Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=36, Recruiting, City of Hope Medical Center | Trial completion date: Apr 2026 --> Mar 2027 | Trial primary completion date: Apr 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Zynlonta (loncastuximab tesirine-lpyl) • Lunsumio (mosunetuzumab-axgb)
    3d
    SOUNDTRACK-D2: AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL (clinicaltrials.gov)
    P3, N=420, Recruiting, AstraZeneca
    Trial initiation date
    |
    doxorubicin hydrochloride • cyclophosphamide • surovatamig (AZD0486)
    5d
    Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma (clinicaltrials.gov)
    P1, N=20, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Trial suspension
    |
    azacitidine • Orencia (abatacept)
    5d
    Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=39, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> May 2027
    Trial completion date
    |
    Imbruvica (ibrutinib) • lenalidomide
    5d
    CD45BE-HSPC + CART-45 Cells (clinicaltrials.gov)
    P1, N=42, Not yet recruiting, University of Pennsylvania | Trial completion date: Apr 2043 --> Jul 2051 | Initiation date: Apr 2026 --> Jul 2026 | Trial primary completion date: Apr 2043 --> Jul 2051
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • CD8 (cluster of differentiation 8) • BCL6 (B-cell CLL/lymphoma 6) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
    6d
    P-CD19CD20-ALLO1-001: P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies (clinicaltrials.gov)
    P1, N=120, Active, not recruiting, Poseida Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    RG6540 • rimiducid (AP1903)
    7d
    Rewiring NADH Metabolism Through NQO1-Mediated Redox Cycling for Targeted Follicular Lymphoma Therapy. (PubMed, Adv Sci (Weinh))
    In a murine FL xenograft model, this approach achieved 85% tumor growth inhibition, while maintaining a favorable safety profile. This work establishes a new therapeutic paradigm for FL, leveraging intrinsic enzyme deficiency to induce tumor-specific, self-amplifying cell death.
    Journal
    |
    NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • NQO1 (NAD(P)H dehydrogenase, quinone 1)
    7d
    KCP-330-009: Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (clinicaltrials.gov)
    P2, N=244, Active, not recruiting, Karyopharm Therapeutics Inc | Recruiting --> Active, not recruiting | Trial completion date: Nov 2027 --> Dec 2026 | Trial primary completion date: Apr 2027 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Xpovio (selinexor)
    8d
    A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P2/3, N=501, Active, not recruiting, Karyopharm Therapeutics Inc | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    cisplatin • gemcitabine • Rituxan (rituximab) • Xpovio (selinexor) • dexamethasone